Effects of Early Emollient Use in Children at High Risk of Atopic Dermatitis: A German Pilot Study
Acta Dermato-Venereologica · 2023
DOI: 10.2340/actadv.v103.5671 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Acta Dermato-Venereologica, 2023. Verfasst von Inken Harder und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel. iharder@dermatology.uni-kiel.de. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Emollients. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Several small studies have indicated that daily emollient use from birth might delay, suppress or prevent atopic dermatitis (AD). Two larger trials did not confirm this; however, a recent smaller study indicated a protective effect if daily emollient use is used in the first 2 months of life. Further research is needed to evaluate the effect of emollient use on development of AD. The current study randomly assigned 50 newborns who were at high risk of developing AD (1:1) to receive general infant skin-care advice (control group), or skin-care advice plus emollient with advice to apply emollient at least once daily until 1 year of age (intervention group). Repeated skin examinations, skin physiology measurements and skin microbiome profiling were performed. Of the children in the intervention and control groups, 28% and 24%, respectively, developed AD (adjusted Relative Risk (RR) 1.19, p = 0.65, adjusted risk difference 0.05). Skin pH decreased and transepidermal water loss and stratum corneum hydration increased over time in both groups with no significant differences. In the intervention group skin microbiome alpha diversity increased earlier, and the abundance of Streptococcus and Staphylococcus species were significantly reduced at month 1. Daily early emollient use in children with high risk of AD was safe, but it did not significantly reduce the risk of developing AD or impact skin physiology development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel. iharder@dermatology.uni-kiel.de.
- Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
- 1Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
- Department of Pediatric Pneumology and Allergy, University Children's Hospital Regensburg (KUNO), Clinic St. Hedwig, Regensburg, Germany.
- Center of Evidence-based Healthcare, University Hospital and Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany.
- Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, 24105 Kiel, Germany.
Zitieren
APA
Harder, I., Stölzl, D., Sander, N., Hartmann, J., Rodriguez, E., Mazur, C., Kerzel, S., Kabesch, M., Küster, D., Schmitt, J., Fölster-Holst, R., Gerdes, S., Emmert, H., & Weidinger, S. (2023). Effects of Early Emollient Use in Children at High Risk of Atopic Dermatitis: A German Pilot Study. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v103.5671
Vancouver
Harder I, Stölzl D, Sander N, Hartmann J, Rodriguez E, Mazur C, et al. Effects of Early Emollient Use in Children at High Risk of Atopic Dermatitis: A German Pilot Study. Acta Dermato-Venereologica. 2023. doi:10.2340/actadv.v103.5671
BibTeX
@article{Harder2023,
author = {Harder, Inken and Stölzl, Dora and Sander, Nicole and Hartmann, Jan and Rodriguez, Elke and Mazur, Carsten and Kerzel, Sebastian and Kabesch, Michael and Küster, Denise and Schmitt, Jochen and Fölster-Holst, Regina and Gerdes, Sascha and Emmert, Hila and Weidinger, Stephan},
title = {Effects of Early Emollient Use in Children at High Risk of Atopic Dermatitis: A German Pilot Study},
journal = {Acta Dermato-Venereologica},
year = {2023},
doi = {10.2340/actadv.v103.5671}
}
EUVIMED